November 2023
Xylazine: A Growing Public Health Concern
By Steven Allen, M.D.
Introduction: Xylazine is an alpha-2 adrenergic receptor agonist, approved by the U.S. Food and Drug Administration (FDA) as a sedative and analgesic in veterinary medicine. In 1962, xylazine was first synthesized by Bayer Pharmaceutics as a potential analgesic, sleeping aid, and anesthetic for human use. However, clinical trials were terminated prematurely due to severe hypotension and clinical nervous system (CNS) depression induced in clinical participants.
Please read Dr. Allen's complete article beginning on Page 4
